Alimentary Pharmacology & Therapeutics · 2017 · 91 citations · 23 references
MedicineInternal MedicinePathologyDiagnostic PathologyGastroenterologyHepatologyBiliary Tract DiseaseBiomarkers Of Liver InjuryCirrhosisLiver DiseaseLiver Function TestsPrognostic AssessmentArea Under The Receiver Operating Characteristic CurveCholestasis BiomarkersLiver Disease PrognosisLiver Disease Risk AssessmentPredictive Risk ScoringPredictive Risk StratificationPrognosis In CirrhosisPrognostic Prediction
BACKGROUND: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. AIM: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. METHODS: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210- patients. RESULTS: (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210- patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210- patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368-94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968-44.180) were associated with poorer outcomes in the whole cohort. CONCLUSIONS: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.
23
2011 · 1.2K citations
Marshall M. Kaplan, M. Eric Gershwin · New England Journal of Medicine · 2005 · 1.2K citations
Medicine, Immunology, Pathology +17
Keith D. Lindor, Eric M. Gershwin, Raoul Poupon et al. · Hepatology · 2009 · 1.1K citations